Last updated on July 2018

Study Comparing Daratumumab Lenalidomide Bortezomib and Dexamethasone (D-RVd) Versus Lenalidomide Bortezomib and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Brief description of study

The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.

Clinical Study Identifier: NCT02874742

Contact Investigators or Research Sites near you

Start Over

Use link at the bottom ...

Cancer Care Northwest
Spokane, WA United States